Anastasia G. Daifotis

TL;DR: It is suggested that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in β-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.

TL;DR: Teplizumab (14-day full-dose) reduced the loss of C-peptide mean area under the curve (AUC) at 2 years versus placebo, a prespecified secondary end point, at 2 Years versus placebo.

TL;DR: Significant differences in efficacy among patient groups are identified suggesting that a key aspect for development of this immune therapy is identification of the demographic, metabolic, and immunologic features that distinguish subjects who are most likely to show beneficial clinical responses.

TL;DR: The risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability are discussed in this paper , where the authors present a risk analysis of the program and its originally intended mission.